- Home
- SGMO
as 01-21-2025 4:00pm EST
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
| Founded: | 1995 | Country: | United States |
| Employees: | N/A | City: | RICHMOND |
| Market Cap: | 488.2M | IPO Year: | 2000 |
| Target Price: | $5.20 | AVG Volume (30 days): | 10.5M |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.70 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.30 - $3.18 | Next Earning Date: | 03-12-2025 |
| Revenue: | $52,291,000 | Revenue Growth: | -74.04% |
| Revenue Growth (this year): | -65.86% | Revenue Growth (next year): | 5.97% |
Latest Sangamo Therapeutics Inc. News
SGMO Breaking Stock News: Dive into SGMO Ticker-Specific Updates for Smart Investing
Insider Monkey
15 days ago
Sangamo Therapeutics Inc. (SGMO): This Small-Cap Stock Is Poised To Outperform in 2025
Zacks
19 days ago
Pharma Stock Roundup: PFE Ends Hemophilia Deal With SGMO & More
Barrons.com
20 days ago
Sangamo Therapeutics Stock Plummets 56% After Pfizer Ends Hemophilia Treatment Partnership
MT Newswires
22 days ago
Top Midday Decliners
MT Newswires
22 days ago
Sangamo Therapeutics Stock Slumps After Pfizer Terminates Hemophilia A Gene Therapy Partnership
MT Newswires
22 days ago
Jefferies Cuts Price Target on Sangamo Therapeutics to $3 From $7, Keeps Buy Rating; Shares Fall
MT Newswires
22 days ago
Top Midday Stories: Sangamo Shares Fall After Pfizer Exits Collaboration; Dave Denies DOJ Allegations
GuruFocus.com
22 days ago
Pfizer Exit Sends Sangamo Plummeting 50%, Casting Doubt on Hemophilia Gene Therapy's Future
Compare SGMO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SGMO Sangamo Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.